Association of the macrophage migration inhibitory factor gene polymorphisms with inflammatory bowel disease

• Published in: Gut Vol. 56; no. 1; pp. 150 - 151
• Main Authors: Oliver, J, Márquez, A, Gómez-Garcia, M, Martinez, A, Mendoza, J L, Vilchez, J R, López-Nevot, M A, Piñero, A, de la Concha, E G, Nieto, A, Urcelay, E, Martín, Dr J
• Format: Journal Article
• Language: English
• Published: England BMJ Publishing Group Ltd and British Society of Gastroenterology 01-01-2007; BMJ Publishing Group LTD; BMJ Group
• Subjects: Adult; Autoimmune diseases; Case-Control Studies; Cohort Studies; Colitis, Ulcerative - genetics; Colon; Confidence intervals; Crohn Disease - genetics; Crohns disease; Female; Genotype; Humans; Inflammatory bowel disease; Inflammatory Bowel Diseases - genetics; Letters; Macrophage Migration-Inhibitory Factors - genetics; Male; Phenotype; Polymorphism, Genetic - genetics; Rodents
• ISSN: 0017-5749; 1468-3288
• DOI: 10.1136/gut.2006.107649

MIF -173 and MIF CATT repeat genotyping was carried out as described previously. 4 Table 1 Clinical features of 558 Spanish patients with Crohn's disease and 472 Spanish patients with ulcerative colitis Cohort 1 Cohort 2 Ulcerative colitis Sex (% M) 49 43 Mean (SD) age at onset (y) 32.3 (13.7) 37.5 (12.3) Mean (SD) disease duration (y) 8.1 (6.4) 11.8 (7.6) Smoking habits (%) Never 51.9 43.2 Ex/current 48.1 56.8 Extraintestinal manifestations 41.7 46.6 Cutaneous (%) 13.7 15.8 Articular (%) 35.8 36.8 Ocular (%) 3.6 3.2 Disease location (%) Left sided 54.8 58.6 Extensive colitis/pancolitis 45.2 41.4 Surgery (%) 15.9 12.1 Immunosuppression (%) 26 23 Crohn's disease Sex (% M) 48 47.1 Mean (SD) age at onset (y) 29.2 (11.7) 27.3 (13.4) <40 (A1) 82.3 80.1 >40 (A2) 17.7 19.9 Mean (SD) disease duration (y) 7.9 (6.1) 11 (6.6) Smoking habits (%) Never 49.2 53.9 Ex/current 50.8 46.1 Disease location Ileal (L1) 41.2 47.9 Colonic (L2) 16.4 16.4 Ileocolonic (L3) 38.7 32.2 Upper GI tract (L4) 3.7 3.4 Disease behaviour Inflammatory (B1) 36.7 43.2 Structuring (B2) 25.3 15.1 Perforating (B3) 38 41.8 Extraintestinal manifestations 37.8 36.9 Surgery (%) 43.2 41.5 Immunosuppression (%) 46.8 45.1 Infliximab (%) 12.3 10.8 GI, gastrointestinal; M, male.